X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs CIPLA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER CIPLA PFIZER/
CIPLA
 
P/E (TTM) x 28.4 44.6 63.6% View Chart
P/BV x 4.5 3.9 115.8% View Chart
Dividend Yield % 0.7 0.3 217.9%  

Financials

 PFIZER   CIPLA
EQUITY SHARE DATA
    PFIZER
Mar-16
CIPLA
Mar-17
PFIZER/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,724622 438.0%   
Low Rs1,611458 351.5%   
Sales per share (Unadj.) Rs440.9181.9 242.4%  
Earnings per share (Unadj.) Rs48.712.9 378.4%  
Cash flow per share (Unadj.) Rs75.829.3 258.5%  
Dividends per share (Unadj.) Rs15.002.00 750.0%  
Dividend yield (eoy) %0.70.4 186.9%  
Book value per share (Unadj.) Rs462.9155.7 297.4%  
Shares outstanding (eoy) m45.75804.51 5.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.93.0 165.5%   
Avg P/E ratio x44.542.0 106.1%  
P/CF ratio (eoy) x28.618.4 155.3%  
Price / Book Value ratio x4.73.5 135.0%  
Dividend payout %30.815.5 198.2%   
Avg Mkt Cap Rs m99,163434,516 22.8%   
No. of employees `0002.923.0 12.5%   
Total wages/salary Rs m2,75826,338 10.5%   
Avg. sales/employee Rs Th6,981.76,349.1 110.0%   
Avg. wages/employee Rs Th954.51,143.0 83.5%   
Avg. net profit/employee Rs Th771.1449.3 171.6%   
INCOME DATA
Net Sales Rs m20,170146,302 13.8%  
Other income Rs m8572,287 37.5%   
Total revenues Rs m21,028148,589 14.2%   
Gross profit Rs m4,31024,758 17.4%  
Depreciation Rs m1,23913,229 9.4%   
Interest Rs m51,594 0.3%   
Profit before tax Rs m3,92312,222 32.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7941,798 99.8%   
Profit after tax Rs m2,22810,354 21.5%  
Gross profit margin %21.416.9 126.3%  
Effective tax rate %45.714.7 311.0%   
Net profit margin %11.07.1 156.1%  
BALANCE SHEET DATA
Current assets Rs m16,29987,370 18.7%   
Current liabilities Rs m7,59433,081 23.0%   
Net working cap to sales %43.237.1 116.3%  
Current ratio x2.12.6 81.3%  
Inventory Days Days6587 75.1%  
Debtors Days Days2662 41.3%  
Net fixed assets Rs m8,622111,567 7.7%   
Share capital Rs m4581,609 28.4%   
"Free" reserves Rs m20,722123,645 16.8%   
Net worth Rs m21,180125,254 16.9%   
Long term debt Rs m2536,454 0.1%   
Total assets Rs m29,137209,532 13.9%  
Interest coverage x755.58.7 8,715.5%   
Debt to equity ratio x00.3 0.4%  
Sales to assets ratio x0.70.7 99.1%   
Return on assets %7.75.7 134.4%  
Return on equity %10.58.3 127.2%  
Return on capital %19.08.5 223.4%  
Exports to sales %0.134.2 0.2%   
Imports to sales %17.58.3 209.6%   
Exports (fob) Rs m1250,050 0.0%   
Imports (cif) Rs m3,52612,203 28.9%   
Fx inflow Rs m5251,066 0.1%   
Fx outflow Rs m14017,678 0.8%   
Net fx Rs m-8833,388 -0.3%   
CASH FLOW
From Operations Rs m3,43623,824 14.4%  
From Investments Rs m-6,991-13,127 53.3%  
From Financial Activity Rs m-619-13,239 4.7%  
Net Cashflow Rs m-4,174-2,478 168.4%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 63.9 20.8 307.2%  
Indian inst/Mut Fund % 7.5 12.2 61.5%  
FIIs % 4.9 23.7 20.7%  
ADR/GDR % 0.0 1.1 -  
Free float % 23.7 26.2 90.5%  
Shareholders   85,207 161,166 52.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jan 17, 2018 (Close)

TRACK PFIZER

PFIZER - DIVIS LABORATORIES COMPARISON

COMPARE PFIZER WITH

MARKET STATS